Frequency Therapeutics scientist
Source: Frequency Therapeutics Twitter

Why Frequency Therapeutics (FREQ) Might Be a Risky Bet for Investors

By

Mar. 24 2021, Published 1:03 p.m. ET

Frequency Therapeutics (FREQ) stock lost 78 percent on March 23. However, the stock was trading higher by 13 percent in pre-market trading on March 24. What’s the forecast for FREQ stock in 2021? Is it a good stock to buy or should investors stay away?

Article continues below advertisement

Founded in 2014, Frequency Therapeutics is a biotechnology company. The company’s lead product candidate, FX-322, is a promising disease-modifying treatment that aims to restore hearing capacity by regenerating auditory hair cells.

buy or sell frequency therapeutics freq stock forecast
Source: Frequency Therapeutics Twitter
Article continues below advertisement

Frequency Therapeutics' (FREQ) stock news

On March 23, FREQ stock plunged significantly after the company announced the top line day-90 interim results from the FX-322 phase 2a study in adults with SNHL (sensorineural hearing loss). The results showed that four weekly injections of FX-322 didn’t demonstrate any improvement in hearing loss versus participants receiving the placebo. However, Frequency did notice that the placebo group experienced a great improvement in hearing, which hadn't been seen in any prior FX-322 trials.

Frequency also released new findings from a separate study that showed that a single injection of FX-322 improved hearing. As a result, the company will focus on developing single-dose FX-322.

Article continues below advertisement

Frequency Therapeutics' stock forecast

According to estimates compiled by MarketBeat, analysts' consensus target price is $37 for FREQ stock, which is 363 percent above its current price. All of the three analysts tracking FREQ stock recommend a buy. None of the analysts recommend a sell. The highest target price of $56 is 601 percent above the stock's current price, while the lowest target price of $20 is 150 percent above the stock's current price.

Two analysts reduced their target prices on FREQ stock after the company announced disappointing trial results on March 23. Oppenheimer reduced its target price from $68 to $20, while B. Riley reduced its target price from $79 to $35.

Article continues below advertisement
buy or sell frequency therapeutics freq stock forecast
Source: Koyfin

FREQ Stock Price

Frequency Therapeutics on WallStreetBets

While retail investors on the popular Reddit group WallStreetBets have been pumping stocks like GameStop and AMC Entertainment, FREQ isn't among the most active stocks on the subreddit. A user going by the name “u/BasicallyElonMusk” highlighted that Yahoo upgraded FREQ stock to a buy rating a day before the company’s disappointing trial results. The post was upvoted over 740 times as of 11:17 a.m. ET on March 24.

Article continues below advertisement

Another user going by the name “u/LividCurry” posted that FREQ stock could reach $60 if the FX-322 drug is approved or the stock could reach $5 if the drug doesn't get approved. The user added that most of the drugs fail in phase 2 clinical trials.

Frequency Therapeutics is a risky investment.

There are several risks that are inherent with an investment in the biotech sector. Frequency Therapeutics doesn’t generate a net income and its business model isn’t fully proven. The company’s overall value depends on the success of its lead candidate FX-322. The product’s value could be impacted negatively if it fails in the clinical study or regulatory authorities don't approve it. Investors face high risk since FREQ is a penny stock.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.